Novartis Ag (NVS) EBIT Growth (3y) (2012 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBIT Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
81.11% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
3.64% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
12.96% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-203.67% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
11.54% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
14.90% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
2.04% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-42.48% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
1.25% |
| Dec 31, 2024 |
167.48% |
| Jun 30, 2024 |
-10.41% |
| Dec 31, 2023 |
144.32% |
| Jun 30, 2023 |
3.96% |
| Mar 31, 2023 |
108.69% |
| Mar 31, 2022 |
13.01% |
| Dec 31, 2021 |
17.66% |
| Sep 30, 2021 |
7.12% |
| Jun 30, 2021 |
30.98% |
| Mar 31, 2021 |
-8.63% |
| Dec 31, 2020 |
6.84% |
| Sep 30, 2020 |
0.43% |
| Jun 30, 2020 |
31.13% |
| Mar 31, 2020 |
-28.69% |
| Mar 31, 2019 |
9,140.50% |
| Dec 31, 2018 |
3.14% |
| Sep 30, 2018 |
973,432.45% |
| Mar 31, 2018 |
10,535.26% |
| Dec 31, 2017 |
9,318.95% |
| Sep 30, 2017 |
9,978.13% |
| Mar 31, 2017 |
7,883.83% |
| Sep 30, 2015 |
-98.97% |
| Mar 31, 2015 |
-2.16% |
| Dec 31, 2014 |
-23.80% |
| Sep 30, 2014 |
3.77% |
| Mar 31, 2014 |
8.75% |
| Sep 30, 2012 |
-48.49% |
| Jun 30, 2012 |
15.63% |
| Mar 31, 2012 |
-46.32% |
